螺旋杆菌与胆管癌的关系

苑博; 李建功; 成雨

doi:10.3969/j.issn.1001-5256.2018.02.050

螺旋杆菌与胆管癌的关系

DOI: 10.3969/j.issn.1001-5256.2018.02.050

1. 滨州医学院
2. 东营市人民医院肝胆外科
3. 滨州医学院附属医院肝胆外科

详细信息

中图分类号: R735.8
计量
- 文章访问数: 1983
- HTML全文浏览量: 60
- PDF下载量: 326
- 被引次数: 0
出版历程
- 出版日期: 2018-02-20

Association between cholangiocarcinoma and Helicobacter pylori

Binzhou Medical University

摘要

摘要:
幽门螺旋杆菌(HP)已被世界卫生组织列为胃癌的第一致癌原,全世界近半数人群有感染史。近年来的研究表明,螺旋杆菌感染与多种其他部位的肿瘤有关。从螺旋杆菌的分类及流行病学、螺旋杆菌与肝胆肿瘤的关系和螺旋杆菌诱导肿瘤发生的机制3个方面介绍螺旋杆菌感染与肝内外胆管肿瘤的研究现状,为进一步探索肿瘤的病因及诊断治疗提供参考,以期待能改善与提高螺杆菌引起胆管癌的诊治与预后。
- 胆管肿瘤 /
- 螺杆菌,幽门 /
- 螺杆菌,肝 /
- 综述
Abstract:
Helicobacter pylori (HP) has been listed as the first carcinogen for gastric cancer by WHO.Recent studies have shown that HP infection is associated with a variety of tumors in other parts.This article introduces the current research on HP infection and intrahepatic/extrahepatic bile duct neoplasms from the aspects of classification and epidemiology of HP, association between HP and hepatobiliary tumors, and mechanism of tumorigenesis induced by HP, in order to provide a reference for further research on tumor etiology and diagnosis/treatment and improve the diagnosis/treatment and prognosis of cholangiocarcinoma caused by HP.
- bile duct neoplasms /
- helicobacter pylori /
- helicobacter hepaticus /
- review

HTML全文

参考文献(49)

[1]RAZUMILAVA N, GORES GJ.Cholangiocarcinoma[J].Lancet, 2014, 383 (9935) :2168-2179.

[2]MA HB, YANG J, YU W, et al.Adjuvant chemoradiotherapy after intrahepatic bile duct carcinoma surgery[J].J Changchun Univ Chin Med, 2016, 32 (5) :1016-1018. (in Chinese) 马宏宾, 杨倞, 喻伟, 等.肝内胆管癌术后辅助性放化疗疗效分析[J].长春中医药大学学报, 2016, 32 (5) :1016-1018.

[3]GHOURI YA, MIAN I, BLECHACZ B.Cancer review:cholangiocarcinoma[J].J Carcinog, 2015, 14:1.

[4]CHEN KL, ZHAI WL.Current treatment of cholangiocarcinoma[J/CD].Chin J Hepatic Surg:Eleetronic Edition, 2017, 6 (6) :447-449. (in Chinese) 陈昆仑, 翟文龙.胆管癌的治疗现状[J/CD].中华肝脏外科手术学电子杂志, 2017, 6 (6) :447-449.

[5]MATSUMOTO K, ONOYAMA T, KAWATA S, et al.Hepatitis B and C virus infection is a risk factor for the development of cholangiocarcinoma[J].Intern Med, 2014, 53 (45) :651-689.

[6]ZHOU HB, HU JY, HU HP.Hepatitis B virus infection and intrahepatic cholangioacrcinoma[J].World J Gastroenterol, 2014, 20 (19) :5721-5729.

[7]WATANAPA P, WATANAPA WB.Liver fluke-associated cholangiocarcinoma[J].Br J Surg, 2002, 89 (12) :962-970.

[8]KATO I, KIDO C.Increased risk of death in thorotrast-exposed patients during the late follow-up period[J].Jpn J Cancer Res, 1987, 78 (11) :1187-1192.

[9]TYSON GL, EL-SERAG HB.Risk factors for cholangiocarcinoma[J].Hepatology, 2011, 54 (1) :173-184.

[10]KHAN SA, DAVIDSON BR, GOLDIN RD, et al.Guidelines for the diagnosis and treatment of cholangiocarcinoma:an update[J].Gut, 2012, 61 (2) :1657-1669.

[11]GOLDIN RD, PATEL NK, THOMAS HC.Hepatitis C and bile duct loss[J].J Clin Pathol, 1996, 49 (4) :836-838.

[12]WARD JM, ANVER MR, HAINES DC, et al.Chronic active hepatitis in mice caused by Helicobacter hepaticus[J].Am J Pathol, 1994, 145 (3) :959-967.

[13]FOX JG, LI X, YAN L, et al.Chronic proliferative hepatitis in A/JCr mice associated with persistent Helicobacter hepaticus infection:a model of helicobacter-induced carcinogenesis[J].Infect Immun, 1996, 64 (5) :1548-1558.

[14]SUERBAUM S, JOSENHANS C, STERZENBACH T, et al.The complete genome sequence of the carcinogenic bacterium Helicobacter hepaticus[J].Proc Natl Acad Sci USA, 2003, 100 (13) :7901-7906.

[15]FRITZ JH, FERRERO RL, PHILPOTT DJ, et al.Nod-like proteins in immunity, inflammation and disease[J].Nat Immunol, 2006, 7 (2) :1250-1257.

[16]KULLBERG MC, ROTHFUCHS AG, JANKOVIC D, et al.Helicobacter hepaticus-induced colitis in interleukin-10-deficient mice:cytokine requirements for the induction and maintenance of intestinal inflammation[J].Infect Immun, 2001, 69 (7) :4232-4241.

[17]ERDMAN SE, POUTAHIDIS T.Cancer inflammation and regulatory T cells[J].Int J Cancer, 2010, 127 (4) :768-779.

[18]FOX JG, SHEN Z, MUTHUPALANI S, et al.Chronic hepatitis, hepatic dysplasia, fibrosis, and biliary hyperplasia in hamsters naturally infected with a novel Helicobacter classified in the H.bilis cluster[J].J Clin Microbiol, 2009, 47 (11) :3673-3681.

[19]PETNICKI-OCWIEJA T, HRNCIR T, LIU YJ, et al.Nod2 is required for the regulation of commensal microbiota in the intestine[J].Proc Natl Acad Sci USA, 2009, 106 (37) :15813-15818.

[20]MANDELL L, MORAN AP, COCCHIARELLA A, et al.Intact gram-negative Helicobacter pylori, Helicobacter felis, and Helicobacter hepaticus bacteria activate innate immunity via toll-like receptor 2 but not toll-like receptor 4[J].Infect Immun, 2004, 72 (11) :6446-6454.

[21]RAO VP, POUTAHIDIS T, GE Z, et al.Innate immune inflammatory response against enteric bacteria Helicobacter hepaticus induces mammary adenocarcinoma in mice[J].Cancer Res, 2006, 66 (2) :7395-7400.

[22]RUDI J, RUDY A, MAIWALD M, et al.Helicobacter sp.are not detectable in bile from German patients with biliary disease[J].Gastroenterology, 1999, 116 (5) :1016-1017.

[23]RICE JM.Helicobacter hepaticus, a recently recognized bacterial pathogen, associated with chronic hepatitis and hepatocellular neoplasia in laboratory mice[J].Emerg Infect Dis, 1995, 1 (4) :129-131.

[24]ERDMAN SE, POUTAHIDIS T, TOMCZAK M, et al.CD4+CD25+regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice[J].Am J Pathol, 2003, 162 (2) :691-702.

[25]RAO VP, POUTAHIDIS T, FOX JG, et al.Breast cancer:should gastrointestinal bacteria be on our radar screen?[J].Cancer Res, 2007, 67 (4) :847-850.

[26]VEIJOLA L, NILSSON I, HALME L, et al.Detection of Helicobacter species in chronic liver disease and chronic inflammatory bowel disease[J].Ann Med, 2007, 39 (43) :554-560.

[27]CHEN W, LI D, CANNAN RJ, et al.Common presence of Helicobacter DNA in the gallbladder of patients with gallstone diseases and controls[J].Dig Liver Dis, 2003, 35 (1) :237-243.

[28]NILSSON HO, TANEERA J, CASTEDAL M, et al.Identification of Helicobacter pylori and other Helicobacter species by PCR, hybridization, and partial DNA sequencing in human liver samples from patients with primary sclerosing cholangitis or primary biliary cirrhosis[J].J Clin Microbiol, 2000, 38 (7) :1072-1076.

[29]ZHOU D, ZHANG Y, GONG W, et al.Are Helicobacter pylori and other Helicobacter species infection associated with human biliary lithiasis?A meta-analysis[J].PLo S One, 2011, 6 (11) :e27390.

[30]MYUNG SJ, KIM MH, SHIM KN, et al.Detection of Helicobacter pylori DNA in human biliary tree and its association with hepatolithiasis[J].Dig Dis Sci, 2000, 45 (3) :1405-1412.

[31]ANANIEVA O, NILSSON I, VOROBJOVA T, et al.Immune responses to bile-tolerant helicobacter species in patients with chronic liver diseases, a randomized population group, and healthy blood donors[J].Clin Diagn Lab Immunol, 2002, 9 (6) :1160-1164.

[32]HAN ML, GONG ZH.Mechanism of action of gut microbiota in hepatobiliary diseases[J].J Clin Hepatol, 2017, 33 (2) :384-388. (in Chinese) 韩美林, 龚振华.肠道菌群在肝胆疾病中的作用机制[J].临床肝胆病杂志, 2017, 33 (2) :384-388.

[33]PANDEY M, SHUKLA M.Helicobacter species are associated with possible increase in risk of hepatobiliary tract cancers[J].Surg Oncol, 2009, 18 (1) :51-56.

[34]ZHOU D, WANG JD, WENG MZ, et al.Infections of Helicobacter spp.in the biliary system are associated with biliary tract cancer:a meta-analysis[J].Eur J Gastroenterol Hepatol, 2013, 25 (3) :447-454.

[35]XUAN SY, LI N, QIANG X, et al.Helicobacter infection in hepatocellular carcinoma tissue[J].World J Gastroenterol, 2006, 12 (15) :2335-2340.

[36]FOX JG, ROGERS AB, WHARY MT, et al.Helicobacter bilis-associated hepatitis in outbred mice[J].Comp Med, 2004, 54 (5) :571-577.

[37]SHOMER NH, DANGLER CA, SCHRENZEL MD, et al.Helicobacter bilis-induced inflammatory bowel disease in scid mice with defined flora[J].Infect Immun, 1997, 65 (11) :4858-4864.

[38]KOBAYASHI T, HARADA K, MIWA K, et al.Helicobacter genus DNA fragments are commonly detectable in bile from patients with extrahepatic biliary diseases and associated with their pathogenesis[J].Dig Dis Sci, 2005, 50 (3) :862-867.

[39]STROFILAS A, LAGOUDIANAKIS EE, SERETIS C, et al.Association of helicobacter pylori infection and colon cancer[J].J Clin Med Res, 2012, 4 (3) :172-176.

[40]FOWSANTEAR W, ARGO E, PATTINSON C, et al.Comparative proteomics of Helicobacter species:the discrimination of gastric and enterohepatic Helicobacter species[J].J Proteomics, 2014, 97 (8) :245-255.

[41]CHIEN CC, TAYLOR NS, GE Z, et al.Identification of cdt B homologues and cytolethal distending toxin activity in enterohepatic Helicobacter spp[J].J Med Microbiol, 2000, 49 (9) :525-534.

[42]TAK PP, FIRESTEIN GS.NF-kappa B:a key role in inflammatory diseases[J].J Clin Invest, 2001, 107 (1) :7-11.

[43]FOX JG, GE Z, WHARY MT, et al.Helicobacter hepaticus infection in mice:models for understanding lower bowel inflammation and cancer[J].Mucosal Immunol, 2011, 4 (1) :22-30.

[44]ALYAMANI EJ, BRANDT P, PENA JA, et al.Helicobacter hepaticus catalase shares surface-predicted epitopes with mammalian catalases[J].Microbiology, 2007, 153 (9) :1006-1016.

[45]STERZENBACH T, BARTONICKOVA L, BEHRENS W, et al.Role of the Helicobacter hepaticus flagellar sigma factor Fli A in gene regulation and murine colonization[J].J Bacteriol, 2008, 190 (19) :6398-6408.

[46]GE Z, FENG Y, WHARY MT, et al.Cytolethal distending toxin is essential for Helicobacter hepaticus colonization in outbred Swiss Webster mice[J].Infect Immun, 2005, 73 (6) :3559-3567.

[47]SMITH JL, BAYLES DO.The contribution of cytolethal distending toxin to bacterial pathogenesis[J].Crit Rev Microbiol, 2006, 32 (2) :227-248.

[48]GE Z, SCHAUER DB, FOX JG.In vivo virulence properties of bacterial cytolethal-distending toxin[J].Cell Microbiol, 2008, 10 (1) :1599-1607.

[49]LIYANAGE NP, MANTHEY KC, DASSANAYAKE RP, et al.Helicobacter hepaticus cytolethal distending toxin causes cell death in intestinal epithelial cells via mitochondrial apoptotic pathway[J].Helicobacter, 2010, 15 (3) :98-107.

施引文献

资源附件(0)

访问统计